
usd jul pm et
summari compani primarili manufactur product orthoped musculoskelet care
nm price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
jul pm stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
hold inc lift
target price reflect
forward price-to-earnings multipl
ep estim
rais price-to-earnings multipl reflect
sooner-than-expect growth ep
vs exceed estim
increas ep
ep sale
increas yoy constant currenc
basi billion expect due
constant currenc cc growth
knee vs manag
expect compani achiev cc revenu
growth in-lin market six
month ahead prior expect
quarter perform encourag
think still earli determin
well rosa compet whether
revers market share loss next
year continu face stronger price
pressur peer price neg
impact sale vs
risk assess reflect zimmer oper
highli competit industri character rel
short product life cycl requir signific number
new product maintain market share mani custom
reimburs medicar restrict
budgetari environ could result price pressur
howev think market leadership posit
divers product offer allevi inher
fiscal year end dec ep estim base cfra
oper earn histor earn report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview zimmer biomet global leader musculoskelet healthcar form
june merger zimmer hold biomet primarili design develop
manufactur market orthopaed reconstruct product sport medicin biolog extrem
trauma product offic base technolog spine craniomaxillofaci thorac product dental
implant relat surgic product market sell product three princip
channel direct healthcar institut hospit stock distributor
healthcar dealer directli dental practic dental laboratori break offer
product categori knee revenu hip dental spine cmf
reconstruct implant use restor function lost due diseas trauma joint
knee hip shoulder elbow knee product total knee replac surgeri joint
replac partial knee reconstruct earli intervent joint preserv hip offer
product total hip replac hip implant procedur involv use bone cement attach
affix prosthet compon surround bone product categori
includ surgic sport medicin biolog foot ankl extrem trauma product
zbh spine product busi manufactur devic surgic instrument deliv comprehens
solut individu back neck pain caus degen condit deform
traumat injuri spine cmf divis includ face skull reconstruct product addit
product fixat stabil bone chest dental product primarili compris dental
reconstruct implant dental prosthet product dental regen product
competit landscap orthopaed broader musculoskelet care industri highli
competit global market zbh knee hip product major competitor includ
depuy synth compani johnson johnson stryker corpor smith nephew plc
spine cmf categori compet global primarili spinal biolog busi
plc depuy synth compani stryker corpor inc globu medic inc
dental implant categori compet primarili nobel biocar hold ag part
corpor straumann hold ag
competit within industri primarili base price technolog innov qualiti reput
custom servic key factor zbh continu success futur abil develop
new product improv exist product technolog
impact major develop receiv mani food drug
administr fda detail observ need in-ne correct zbh warsaw
indiana-bas manufactur plant earli continu remedi manufactur issu
origin expect warsaw plant issu resolv howev zbh manag
expect februari readi fda reinspect although orthoped surgeri
tend sticki custom extend period zbh manufactur under-capac may led
signific market share loss manufactur remedi process also result inventori
constraint caus cut guidanc multipl time
june zimmer acquir biomet billion connect transact zimmer
chang name zimmer biomet ticker symbol new york stock exchang
zmh combin compani leader musculoskelet market juli zimmer acquir
ldr hold billion ldr medic devic compani focus proprietari surgic
technolog treatment patient suffer spinal disord
financi trend revenu dec increas billion billion
adjust ep declin year-over-year prior-year reflect five-year
compound annual growth rate compound-annual-growth-rate growth pressur zbh remedi
effort manufactur plant warsaw indiana decemb zbh net debt total
capit leverag ratio net debt ebitda zbh free cash flow defin cash
flow oper less capit expenditur expand billion billion
senior vice presid
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
bullish sinc juli technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
equip sub-industri next month
neutral continu expect compani
sub-industri achiev robust organ
growth posit macroeconom environ
compani gener benefit new
product launch laxer food drug
administr fda technolog advanc
sub-industri also mani product area
histor recession-resist
equip use non-elect procedur
howev valuat health care equip
compani elev rel
composit suggest posit
fundament reflect share
think higher valuat
sub-industri mostli warrant
strong recent margin expans revenu
growth associ robust product
expect sub-industri earn rise
high-single-digit percentag driven
continu pipelin innov new product
emerg market expans speed
new product come market
increas recent year
success effort fda reduc
approv time medic devic
time see price pressur incess
headwind medic equip compani
impact china-u trade war appear
insignific far medic
equip compani especi sinc
base medic equip manufactur
sourc insignific amount product
input china addit
chines govern seek lower health
care cost provid better health care
insul medic equip
sub-industri mount trade tension
larg medic equip target
chines tariff mean certain
compani
like
hurt trade tension howev bigger
concern medic equip
manufactur potenti trade
tension caus signific slowdown
possibl threat state american
health care system lawsuit texa
rule unconstitut
current expect upheld upon
appeal although decis could take
coupl year reach democrat
took control hous repres
period think
see substanti effort
republican trump administr
tri repeal
anoth legisl issu could impact
medic equip manufactur
potenti return medic devic tax
medic devic tax suspend
end congress fail
repeal suspend tax medic
devic manufactur could significantli
gener see posit long-term
fundament includ increas global
demand cost-effect value-bas
health care age popul rise
outlay result steadi flow
innov product revenu growth
year-to-d june
vs increas valu
 composit index
vs declin composit
base index
five-year market price perform jul
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
analyst research note compani news
pm et cfra reiter sell opinion share zimmer biomet
hold inc lift target price
reflect forward price-to-earnings multipl ep estim
rais price-to-earnings multipl reflect sooner-than-expect growth
ep vs exceed estim increas
ep ep sale
increas yoy constant currenc basi billion
expect due constant currenc cc growth knee vs
manag expect compani achiev cc revenu growth in-lin
market six month ahead prior expect
quarter perform encourag think still earli
determin well rosa compet whether revers market share
loss next year continu face stronger price pressur
peer price neg impact sale vs
hold inc maintain target
below-p ep estim lower multipl
reflect continu remedi effort address fda concern initi
highlight novemb ep vs lower
estim maintain ep lower ep
sale increas constant currenc billion
strengthen dollar stronger neg expect quarter
expect even stronger headwind vs constant
currenc basi revenu grew america flat emea grew
asia pacif reassur investor two largest upcom
project persona revis system new rosa robot applic
progress well await regulatori approv expect year
compani set sustain revenu growth
hold inc lift target
below-p ep estim lower
multipl reflect zbh on-going effort remedi violat key
plant highlight fda initi novemb ep vs
higher estim lower ep
ep sale increas
constant currenc billion constant currenc basi
revenu grew america declin emea grew
asia pacif cautious optimist zbh suppli recoveri
remedi effort compani think achiev
above-market growth rate though expect constant
et cfra lower opinion share sell
hold lower price target
reflect forward price-to-earnings multipl ep estim
reduc ep ep
believ consensu expect regard abil
slow market share loss optimist see long-term potenti
recent launch rosa knee system total knee arthroplasti tka
think factor limit near-term success rosa
sale exampl rosa key competit mako system fda
approv tka almost four year rosa earli move enabl
establish robust data set mako tka creat reput
leader robot-assist knee replac declin econom
condit consum sentiment may also prove unfavor
environ launch sale system rosa especi given
pm et cfra maintain hold opinion share zimmer biomet
hold inc rais target
ep estim -- peer-averag due
continu remedi effort need address fda concern ep
vs consensu maintain ep
estim respect sale increas yoy
constant currenc basi volume/mix improv contribut
growth price neg impact constant currenc
basi revenu yoy america
emea asia pacif respect continu focu short-term
prioriti set achiev long-term in-line-with-market growth
prioriti includ address suppli chain issu optim talent
structur ensur success recent upcom product launch
rosa robot platform earli stage limit launch
pm et cfra maintain hold opinion share zimmer biomet
hold inc lower target
ep estim -- peer-averag due continu
remedi effort need address fda concern ep vs
consensu lower ep estim
start sale rose yoy constant currenc
billion constant currenc basi revenu yoy
america grew emea asia pacif respect
 spine fastest grow product categori quarter
experienc constant currenc sale increas full year
grew cash oper activ impress versu
declin aid solid progress made suppli recoveri
reduct back order expect year compani
set sustain revenu growth beyond /colin
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
